EHA 2023 | Update on the guidelines for the diagnosis, grading & management of ICAHT following CAR-T therapy
Kai Rejeski, MD, LMU Munich, Munich, Germany, discusses the recently developed consensus guidelines for the diagnosis, grading, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR-T therapy. Hematological toxicity is the most common grade ≥3 adverse event following CAR-T therapy and can predispose to infections. However, current diagnostic and grading practices are very variable. A joint effort between the EBMT and EHA was formed to harmonize the grading and management of this adverse event. This new grading system separates early and late ICAHT, and provides tailored treatment recommendations based on ICAHT severity. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Honoraria; Kite/Gilead: Other: Travel Support, Research Funding
